Latest Xarleto news
Rivaroxaban Does Not Reduce VTE Incidence in High-Risk Cancer Patients
by modernClinician Editorial Team
In high-risk ambulatory patients with cancer, the incidence of venous thromboembolism or death due to venous thromboembolism during 180 days is not significantly reduced for rivaroxaban compared with placebo, according to a study published in the Feb. 21 issue of the New England Journal of Medicine.
ASH: Rivaroxaban Prevents Blood Clots in At-Risk Cancer Patients
by modernClinician Editorial Team
Rivaroxaban can prevent venous thromboembolism in cancer patients at increased risk, according to a study presented at the annual meeting of the American Society of Hematology, held from Dec. 1 to 4 in San Diego.
No Clear Benefit for Rivaroxaban After Hospital Discharge
by modernClinician Editorial Team
Rivaroxaban does not lower risk of symptomatic venous thromboembolism and related death in medical patients after hospital discharge, compared to placebo, according to a study published in the Sept. 20 issue of the New England Journal of Medicine.
Rivaroxaban Linked to Low VTE Recurrence in Active Cancer
by modernClinician Editorial Team
For patients with active cancer and venous thromboembolism (VTE), rivaroxaban is associated with lower VTE recurrence compared with dalteparin, but with elevated clinically relevant non-major bleeding, according to a study published online May 10 in the Journal of Clinical Oncology.
Aircrew Face Higher Odds of Radiation-Related Cancer Deaths 
Preoperative Chemo + Immunotherapy Combo Shrinks Head, Neck Cancer Tumors 
Couples" Coping Skills Help Reduce Depression in GI Cancer Survivors 
Genomic Newborn Screening Could ID Cancer Predisposition Syndrome 
Diltiazem Linked to Increased Risk for Bleeding Complications in A-Fib 
Six Additional Weeks of Rivaroxaban Reduces Recurrent VTE 
Rivaroxaban Improves Clinical Outcomes After COVID-19 Hospitalization 
Rivaroxaban OK for Stroke Prevention in Cancer Patients Monthly Specialist Briefings
Stay Connected
